Antiplatelet efficacy of ticagrelor versus clopidogrel in Mediterranean patients with diabetes mellitus and chronic coronary syndromes: A crossover pharmacodynamic investigation

Antiplatelet efficacy of ticagrelor versus clopidogrel in Mediterranean patients with diabetes mellitus and chronic coronary syndromes: A crossover pharmacodynamic investigation

IntroductionPatients with diabetes mellitus (DM) have augmented platelet reactivity and diminished responsiveness to clopidogrel. Ticagrelor, a more potent P2Y12 inhibitor, is clinically superior to clopidogrel in acute coronary syndromes, although its role in chronic coronary syndromes (CCS) is sti...

Full description

Bibliographic Details
Main Authors: Ana Lucrecia Marcano, Montserrat Gracida, Gerard Roura, Josep Gomez-Lara, Rafael Romaguera, Luis Teruel, Lara Fuentes, Guillem Muntané-Carol, Oona Meroño, Silvia Gabriela Sosa, Joan Antoni Gómez-Hospital, Josep Comin-Colet, José Luis Ferreiro
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
ticagrelor
chronic coronary syndrome
antiplatelet therapy
high platelet reactivity
diabetes mellitus
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2022.1057331/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2022.1057331/full

Similar Items